董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Iwicki | 男 | Director | 52 | 7.42万美元 | 未持股 | 2019-03-31 |
| Aaron Royston | 男 | Director | 34 | 未披露 | 未持股 | 2019-03-31 |
| Seth L. Harrison | 男 | Director | 58 | 未披露 | 未持股 | 2019-03-31 |
| Jane P. Henderson | 女 | Director | 53 | 未披露 | 未持股 | 2019-03-31 |
| Graham Walmsley | 女 | Director | 32 | 未披露 | 未持股 | 2019-03-31 |
| Andrew Cheng | 男 | President, Chief Executive Officer and Director | 52 | 104.77万美元 | 未持股 | 2019-03-31 |
| Kevin Bitterman | 男 | Director | 42 | 未披露 | 未持股 | 2019-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Young | 男 | Executive Vice President and Chief Operating Officer | 49 | 65.95万美元 | 未持股 | 2019-03-31 |
| William White | 男 | Executive Vice President, Chief Financial Officer and Head of Corporate Development | 46 | 未披露 | 未持股 | 2019-03-31 |
| Timothy Rolph | 男 | Chief Scientific Officer | 65 | 65.95万美元 | 未持股 | 2019-03-31 |
| Kitty Yale | 女 | Chief Development Officer | 47 | 32.03万美元 | 未持股 | 2019-03-31 |
| Andrew Cheng | 男 | President, Chief Executive Officer and Director | 52 | 104.77万美元 | 未持股 | 2019-03-31 |
董事简历
中英对照 | 中文 | 英文- Mark Iwicki
-
Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from Augt 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University. - Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
- Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from Augt 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University.
- Aaron Royston
-
Aaron Royston自2017年9月以来一直担任我们的董事会成员。Royston博士是Venbio Partners（一家生命科学投资公司）的管理合伙人，自2015年11月起在Venbio Partners任职。加入Venbio Partners之前，Royston从2014年7月到2015年11月在Vivo Capital（一家全球生命科学投资公司）任职。此前，他曾任职Bain&Company（从2013年7月到2014年7月），在那里他曾为生物技术公司提供广泛的战略和运营问题的建议。职业生涯早期，Royston博士在西奈山医学中心（Mount Sinai Medical Center）协调临床研究，在那里他的研究已经发表并在多个医学期刊和会议上发表。2011年，Royston博士因其在技术和创新方面的工作而被奥巴马政府认可为变革的拥护者。Royston博士此前曾在Akero Therapeutics（一家上市生物技术公司）和Menlo Therapeutics，Inc.（一家上市生物技术公司）的董事会任职，目前在几家私人公司的董事会任职。Royston博士在杜克大学（Duke University）获得生物科学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得医学博士学位和工商管理硕士学位。
Aaron Royston,has served as a member of Rayzebio, Inc. board of directors since August 2020. Dr. Royston serves as a managing partner at venBio Partners, a life sciences investment firm, and has been employed by venBio Partners since 2015. Prior to joining venBio Partners, Dr. Royston served as a senior associate at Vivo Capital, a global life sciences investment firm from July 2014 until November 2015. Previously, Dr. Royston served as a consultant at Bain & Company, Inc. from July 2013 until July 2014 where he advised biotechnology companies on a broad range of strategic and operational issues. Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. In 2011, Dr. Royston was recognized by the Obama Administration as a Champion of Change for his work in technology and innovation. Dr. Royston previously served on the board of directors of Ventyx Biosciences, a biotechnology company, from March 2021 until January 2023, Akero Therapeutics, a biotechnology company, from June 2018 until August 2019, and Menlo Therapeutics Inc., a biotechnology company, from July 2017 until August 2019. Dr. Royston currently serves on the board of directors of several private companies, including Attovia Therapeutics, Inc., an early-stage company, Ablaze Pharmaceuticals Inc., a biopharmaceutical company, Neurogastrx, Inc., a pharmaceutical company, Swift Health Systems, Inc., a medtech company, Histowiz, Inc., a biotechnology company and 35Pharma Inc, a biotechnology company. Dr. Royston received a B.S. in biological sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania. - Aaron Royston自2017年9月以来一直担任我们的董事会成员。Royston博士是Venbio Partners（一家生命科学投资公司）的管理合伙人，自2015年11月起在Venbio Partners任职。加入Venbio Partners之前，Royston从2014年7月到2015年11月在Vivo Capital（一家全球生命科学投资公司）任职。此前，他曾任职Bain&Company（从2013年7月到2014年7月），在那里他曾为生物技术公司提供广泛的战略和运营问题的建议。职业生涯早期，Royston博士在西奈山医学中心（Mount Sinai Medical Center）协调临床研究，在那里他的研究已经发表并在多个医学期刊和会议上发表。2011年，Royston博士因其在技术和创新方面的工作而被奥巴马政府认可为变革的拥护者。Royston博士此前曾在Akero Therapeutics（一家上市生物技术公司）和Menlo Therapeutics，Inc.（一家上市生物技术公司）的董事会任职，目前在几家私人公司的董事会任职。Royston博士在杜克大学（Duke University）获得生物科学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得医学博士学位和工商管理硕士学位。
- Aaron Royston,has served as a member of Rayzebio, Inc. board of directors since August 2020. Dr. Royston serves as a managing partner at venBio Partners, a life sciences investment firm, and has been employed by venBio Partners since 2015. Prior to joining venBio Partners, Dr. Royston served as a senior associate at Vivo Capital, a global life sciences investment firm from July 2014 until November 2015. Previously, Dr. Royston served as a consultant at Bain & Company, Inc. from July 2013 until July 2014 where he advised biotechnology companies on a broad range of strategic and operational issues. Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. In 2011, Dr. Royston was recognized by the Obama Administration as a Champion of Change for his work in technology and innovation. Dr. Royston previously served on the board of directors of Ventyx Biosciences, a biotechnology company, from March 2021 until January 2023, Akero Therapeutics, a biotechnology company, from June 2018 until August 2019, and Menlo Therapeutics Inc., a biotechnology company, from July 2017 until August 2019. Dr. Royston currently serves on the board of directors of several private companies, including Attovia Therapeutics, Inc., an early-stage company, Ablaze Pharmaceuticals Inc., a biopharmaceutical company, Neurogastrx, Inc., a pharmaceutical company, Swift Health Systems, Inc., a medtech company, Histowiz, Inc., a biotechnology company and 35Pharma Inc, a biotechnology company. Dr. Royston received a B.S. in biological sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania.
- Seth L. Harrison
-
SethL.Harrison自2015年7月以来一直担任我们的董事会主席。他曾担任Apple Tree Partners公司（风险投资公司，他于1999年创立）的管理合伙人。创立Apple Tree Partners公司之前，Harrison博士曾担任Oak Investment Partners公司（一家风险投资和私募股权公司）的普通合伙人，以及Sevin Rosen Funds公司（一家技术风险投资公司）的风险合伙人。哈里森博士目前担任制药公司BraeburnPharmaceuticals，Inc.、免疫治疗公司Elstar Therapeutics，Inc.、基因治疗公司Limelight Bio，Inc.以及几家私营公司的董事会主席。Harrison博士拥有普林斯顿大学（Princeton University）的A.B.和哥伦比亚大学（Columbia University）的M.D.和M.B.A.。
Seth L. Harrison,serves as Managing Partner at Apple Tree Partners, a venture capital firm, which he founded in 1999. Prior to founding Apple Tree Partners, Dr. Harrison served as a General Partner at Oak Investment Partners, a venture capital and private equity firm, and as a Venture Partner at Sevin Rosen Funds, a technology-focused venture capital firm. Dr. Harrison currently serves as a member of the board of directors of Akero Therapeutics, Inc., a public biopharmaceutical company. Dr. Harrison also serves as the chair of the boards of directors of Braeburn Inc., a pharmaceutical company, Marengo Therapeutics, Inc., an immunotherapy company, and Galvanize Therapeutics, Inc., a medical device company, as well as a director for numerous other private companies. Dr. Harrison holds an A.B. from Princeton University and an M.D. and M.B.A. from Columbia University. - SethL.Harrison自2015年7月以来一直担任我们的董事会主席。他曾担任Apple Tree Partners公司（风险投资公司，他于1999年创立）的管理合伙人。创立Apple Tree Partners公司之前，Harrison博士曾担任Oak Investment Partners公司（一家风险投资和私募股权公司）的普通合伙人，以及Sevin Rosen Funds公司（一家技术风险投资公司）的风险合伙人。哈里森博士目前担任制药公司BraeburnPharmaceuticals，Inc.、免疫治疗公司Elstar Therapeutics，Inc.、基因治疗公司Limelight Bio，Inc.以及几家私营公司的董事会主席。Harrison博士拥有普林斯顿大学（Princeton University）的A.B.和哥伦比亚大学（Columbia University）的M.D.和M.B.A.。
- Seth L. Harrison,serves as Managing Partner at Apple Tree Partners, a venture capital firm, which he founded in 1999. Prior to founding Apple Tree Partners, Dr. Harrison served as a General Partner at Oak Investment Partners, a venture capital and private equity firm, and as a Venture Partner at Sevin Rosen Funds, a technology-focused venture capital firm. Dr. Harrison currently serves as a member of the board of directors of Akero Therapeutics, Inc., a public biopharmaceutical company. Dr. Harrison also serves as the chair of the boards of directors of Braeburn Inc., a pharmaceutical company, Marengo Therapeutics, Inc., an immunotherapy company, and Galvanize Therapeutics, Inc., a medical device company, as well as a director for numerous other private companies. Dr. Harrison holds an A.B. from Princeton University and an M.D. and M.B.A. from Columbia University.
- Jane P. Henderson
-
JaneP.Henderson自2018年1月以来一直担任我们的董事会成员。亨德森女士自2018年6月起担任Turnstone Biologics（一家私营生物技术公司）的首席财务官。从2017年1月至2018年6月，亨德森女士担任VoyagerTherapeutics，Inc.公司（一家上市的临床阶段基因治疗公司）的首席财务官兼高级副总裁，企业发展。2013年至2016年，亨德森担任私营制药公司Kolltan制药公司的高级副总裁，首席财务官和商务官，2010年至2012年，亨德森担任ISTA Pharmaceuticals，Inc.的业务发展Vice President，ISTA Pharmaceuticals，Inc.是一家上市的专业制药公司，直到被Bausch&Lomb Incorporated收购。此前，亨德森女士曾担任Axerion Therapeutics，Inc.的首席财务官兼业务开发主管，以及Panacos Pharmaceuticals，Inc.的首席财务官兼首席商务官，这两家公司都是私营生物技术公司。除了行业经验外，亨德森女士还在汇丰控股有限公司、Canadian Imperial Bank of Commerce、雷曼兄弟和所罗门兄弟公司担任董事总经理和其他高级职务。亨德森女士目前在Sesen Bio Inc.和AkeroTherapeutics，Inc.的董事会任职，这两家公司都是公开上市的生物技术公司。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
Jane P. Henderson has served as Adagio Therapeutics, Inc. Chief Financial Officer since December 2020. She has served as a member of IVERIC bio, Inc. of directors since January 2018. Ms. Henderson has served as chief financial officer of Turnstone Biologics, a privately-held biotechnology company, since June 2018. From January 2017 to June 2018 Ms. Henderson served as chief financial officer and senior vice president, corporate development at Voyager Therapeutics, Inc., a publicly-traded clinical-stage gene therapy company. From 2013 to 2016 Ms. Henderson served as senior vice president, chief financial and business officer of Kolltan Pharmaceuticals, Inc., which was a privately held pharmaceutical company, and from 2010 to 2012 Ms. Henderson served as vice president, business development of ISTA Pharmaceuticals, Inc, a publicly-traded specialty pharmaceutical company, until its acquisition by Bausch & Lomb Incorporated. Previously, Ms. Henderson served as chief financial officer and head of business development at Axerion Therapeutics, Inc., and chief financial officer and chief business officer of Panacos Pharmaceuticals, Inc, both privately held biotechnology companies. In addition to her industry experience, Ms. Henderson was managing director and held other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the boards of directors of Sesen Bio Inc. and Akero Therapeutics, Inc., both of which are publicly traded biotechnology companies. Ms. Henderson received a B.S. in psychology from Duke University. - JaneP.Henderson自2018年1月以来一直担任我们的董事会成员。亨德森女士自2018年6月起担任Turnstone Biologics（一家私营生物技术公司）的首席财务官。从2017年1月至2018年6月，亨德森女士担任VoyagerTherapeutics，Inc.公司（一家上市的临床阶段基因治疗公司）的首席财务官兼高级副总裁，企业发展。2013年至2016年，亨德森担任私营制药公司Kolltan制药公司的高级副总裁，首席财务官和商务官，2010年至2012年，亨德森担任ISTA Pharmaceuticals，Inc.的业务发展Vice President，ISTA Pharmaceuticals，Inc.是一家上市的专业制药公司，直到被Bausch&Lomb Incorporated收购。此前，亨德森女士曾担任Axerion Therapeutics，Inc.的首席财务官兼业务开发主管，以及Panacos Pharmaceuticals，Inc.的首席财务官兼首席商务官，这两家公司都是私营生物技术公司。除了行业经验外，亨德森女士还在汇丰控股有限公司、Canadian Imperial Bank of Commerce、雷曼兄弟和所罗门兄弟公司担任董事总经理和其他高级职务。亨德森女士目前在Sesen Bio Inc.和AkeroTherapeutics，Inc.的董事会任职，这两家公司都是公开上市的生物技术公司。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
- Jane P. Henderson has served as Adagio Therapeutics, Inc. Chief Financial Officer since December 2020. She has served as a member of IVERIC bio, Inc. of directors since January 2018. Ms. Henderson has served as chief financial officer of Turnstone Biologics, a privately-held biotechnology company, since June 2018. From January 2017 to June 2018 Ms. Henderson served as chief financial officer and senior vice president, corporate development at Voyager Therapeutics, Inc., a publicly-traded clinical-stage gene therapy company. From 2013 to 2016 Ms. Henderson served as senior vice president, chief financial and business officer of Kolltan Pharmaceuticals, Inc., which was a privately held pharmaceutical company, and from 2010 to 2012 Ms. Henderson served as vice president, business development of ISTA Pharmaceuticals, Inc, a publicly-traded specialty pharmaceutical company, until its acquisition by Bausch & Lomb Incorporated. Previously, Ms. Henderson served as chief financial officer and head of business development at Axerion Therapeutics, Inc., and chief financial officer and chief business officer of Panacos Pharmaceuticals, Inc, both privately held biotechnology companies. In addition to her industry experience, Ms. Henderson was managing director and held other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the boards of directors of Sesen Bio Inc. and Akero Therapeutics, Inc., both of which are publicly traded biotechnology companies. Ms. Henderson received a B.S. in psychology from Duke University.
- Graham Walmsley
-
Graham Walmsley于本招股说明书发布之日成为我们的董事会成员，自2019年8月起担任总部位于旧金山的专注于生物技术的投资合伙企业Logos Global Management，LP的普通合伙人。2016年7月至2019年8月，他是领先的梦百合投资公司Versant Ventures的负责人。他于2017年6月至2019年3月担任针对非酒精性脂肪性肝炎和肝纤维化的疗法开发商Jecure Therapeutics的业务开发主管。从2018年4月至2018年12月，他担任神经再生药物开发商Pipeline Therapeutics的业务开发主管。从2012年7月到2016年6月，他曾担任Stanford Hospital&Clinics公司的附属实习生。他目前是ALX Oncology纳斯达克股票代码:ALXO和Akero Therapeutics（纳斯达克股票代码:AKRO）的董事会成员。
Graham Walmsley, a Board member serving as chair of our Compensation Committee and member of our Audit Committee and Nominating Committee, is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies. Since January 2019 Liz has served as President and CEO of UroGen Pharma. Prior to UroGen, from February 2018 to January 2019 Liz was CEO of Novartis Oncology and a member of the Novartis Executive Committee. She previously was at Pfizer Inc. from March 2009 to January 2019 where she held numerous leadership positions, including Global President of Oncology, President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology. Prior to Pfizer, Liz held positions at Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson & Johnson. She started her career at Kraft Foods Group, Inc. Liz received a B.A. from the University of Louisiana and an M.B.A. from Saint Joseph's University. - Graham Walmsley于本招股说明书发布之日成为我们的董事会成员，自2019年8月起担任总部位于旧金山的专注于生物技术的投资合伙企业Logos Global Management，LP的普通合伙人。2016年7月至2019年8月，他是领先的梦百合投资公司Versant Ventures的负责人。他于2017年6月至2019年3月担任针对非酒精性脂肪性肝炎和肝纤维化的疗法开发商Jecure Therapeutics的业务开发主管。从2018年4月至2018年12月，他担任神经再生药物开发商Pipeline Therapeutics的业务开发主管。从2012年7月到2016年6月，他曾担任Stanford Hospital&Clinics公司的附属实习生。他目前是ALX Oncology纳斯达克股票代码:ALXO和Akero Therapeutics（纳斯达克股票代码:AKRO）的董事会成员。
- Graham Walmsley, a Board member serving as chair of our Compensation Committee and member of our Audit Committee and Nominating Committee, is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies. Since January 2019 Liz has served as President and CEO of UroGen Pharma. Prior to UroGen, from February 2018 to January 2019 Liz was CEO of Novartis Oncology and a member of the Novartis Executive Committee. She previously was at Pfizer Inc. from March 2009 to January 2019 where she held numerous leadership positions, including Global President of Oncology, President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology. Prior to Pfizer, Liz held positions at Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson & Johnson. She started her career at Kraft Foods Group, Inc. Liz received a B.A. from the University of Louisiana and an M.B.A. from Saint Joseph's University.
- Andrew Cheng
-
Andrew Cheng自2018年9月起担任我们的总裁兼首席执行官。在加入公司之前，程博士曾于2018年3月至2018年9月在生物技术公司吉利德科学公司担任首席医疗官，2015年2月至2018年9月担任执行Vice President，2009年2月至2015年2月担任高级副总裁。在他近20年的任期内，他负责HIV项目的临床开发，产生了11个FDA/EMA批准的产品。他过去的职责还包括医疗事务和开发运营部监管事务的创建、临床运营、药物警戒、项目管理、临床药理学和生物识别，涵盖多个治疗领域的临床开发支持，包括肿瘤学、炎症、呼吸、心血管、艾滋病毒和肝脏疾病。Cheng博士曾在生物技术公司Syntimmune，Inc.的董事会任职，该公司被Alexion收购。Cheng博士拥有The Johns Hopkins University生物学学士学位和Columbia University College of Physicians and Surgeons细胞和分子生物学硕士学位和博士学位。他在加州大学洛杉矶分校（UCLA）完成了内科住院医师资格，并获得了内科委员会认证。
Andrew Cheng,has served as a member of Board since May 2017. Dr. Cheng has served as the President and Chief Executive Officer, as well as a director, of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since September 2018. Dr. Cheng has served as non-executive director for MorphoSys AG (Nasdaq: MOR) from May 2022 until its acquisition in February 2024. From August 2019 to May 2022, Dr. Cheng served as a non-executive director for Arbutus Biopharma Corporation (Nasdaq: ABUS), a biopharmaceutical company. Before joining Akero, Dr. Cheng was at Gilead as Chief Medical Officer from March 2018 to September 2018, Executive Vice President from February 2015 to September 2018, and Senior Vice President from February 2009 to February 2015. From April 2018 to November 2018, Dr. Cheng served on the board of directors of Syntimmune, Inc., a biotechnology company, which was acquired by Alexion Pharmaceuticals Inc. Dr. Cheng holds a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine. - Andrew Cheng自2018年9月起担任我们的总裁兼首席执行官。在加入公司之前，程博士曾于2018年3月至2018年9月在生物技术公司吉利德科学公司担任首席医疗官，2015年2月至2018年9月担任执行Vice President，2009年2月至2015年2月担任高级副总裁。在他近20年的任期内，他负责HIV项目的临床开发，产生了11个FDA/EMA批准的产品。他过去的职责还包括医疗事务和开发运营部监管事务的创建、临床运营、药物警戒、项目管理、临床药理学和生物识别，涵盖多个治疗领域的临床开发支持，包括肿瘤学、炎症、呼吸、心血管、艾滋病毒和肝脏疾病。Cheng博士曾在生物技术公司Syntimmune，Inc.的董事会任职，该公司被Alexion收购。Cheng博士拥有The Johns Hopkins University生物学学士学位和Columbia University College of Physicians and Surgeons细胞和分子生物学硕士学位和博士学位。他在加州大学洛杉矶分校（UCLA）完成了内科住院医师资格，并获得了内科委员会认证。
- Andrew Cheng,has served as a member of Board since May 2017. Dr. Cheng has served as the President and Chief Executive Officer, as well as a director, of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since September 2018. Dr. Cheng has served as non-executive director for MorphoSys AG (Nasdaq: MOR) from May 2022 until its acquisition in February 2024. From August 2019 to May 2022, Dr. Cheng served as a non-executive director for Arbutus Biopharma Corporation (Nasdaq: ABUS), a biopharmaceutical company. Before joining Akero, Dr. Cheng was at Gilead as Chief Medical Officer from March 2018 to September 2018, Executive Vice President from February 2015 to September 2018, and Senior Vice President from February 2009 to February 2015. From April 2018 to November 2018, Dr. Cheng served on the board of directors of Syntimmune, Inc., a biotechnology company, which was acquired by Alexion Pharmaceuticals Inc. Dr. Cheng holds a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine.
- Kevin Bitterman
-
Kevin Bitterman，自2006年8月起，他一直是我们的董事会成员。自2004年起，他一直担任Polaris Partners（ 或者 Polaris）的负责人，专注于对生命科学公司的投资。在加入Polaris 之前，他完成了Harvard Medical School遗传学的哲学博士的学习。他的博士研究专注于对热量限制摄入的分子调控和对新型蛋白去乙酰化酶类的调制。他是共同创始了Sirtris Pharmaceuticals, Inc.，被 GlaxoSmithKline收购，是Visterra Inc的创始首席执行官。除了代表Polaris担任我们公司的董事以外，目前他代表Polaris担任InSeal Medical, Kala Pharmaceuticals, Neuronetics, Inc., Visterra, Inc., TARIS Biomedical， 和 Vets First Choice的董事。此外，他是 Arsenal Medical 和 480 Biomedical的董事会观察员。他取得了 Harvard Medical School的遗传学哲学博士学位，以及Rutgers College的生物学学士学位。
Kevin Bitterman has served as a member of our board of directors since June 2018. Dr. Bitterman currently serves as a partner at venture firm Atlas Venture, or Atlas, a venture capital firm, where he has been employed since June 2017 and where he focuses on investments in life science companies. Prior to joining Atlas in June 2017 Dr. Bitterman was a partner at Polaris Partners, an investment firm, as a member of the healthcare team since July 2004. Dr. Bitterman was also the founding CEO at Editas Medicine Inc., a pharmaceutical company, Visterra Inc., a biotechnology company, and Morphic Rock, LLC, a biotechnology company. During the past five years, Dr. Bitterman has served on the board of directors of Editas Medicine, Inc., Kala Pharmaceuticals, Inc., a pharmaceutical company, Genocea Biosciences, Inc., a biosciences company, as well as on the board of directors of several private companies. Dr. Bitterman also serves as board chair of the New England Venture Capital Association. Dr. Bitterman received a B.A. in biology from Rutgers College and a Ph.D. in genetics from Harvard Medical School. - Kevin Bitterman，自2006年8月起，他一直是我们的董事会成员。自2004年起，他一直担任Polaris Partners（ 或者 Polaris）的负责人，专注于对生命科学公司的投资。在加入Polaris 之前，他完成了Harvard Medical School遗传学的哲学博士的学习。他的博士研究专注于对热量限制摄入的分子调控和对新型蛋白去乙酰化酶类的调制。他是共同创始了Sirtris Pharmaceuticals, Inc.，被 GlaxoSmithKline收购，是Visterra Inc的创始首席执行官。除了代表Polaris担任我们公司的董事以外，目前他代表Polaris担任InSeal Medical, Kala Pharmaceuticals, Neuronetics, Inc., Visterra, Inc., TARIS Biomedical， 和 Vets First Choice的董事。此外，他是 Arsenal Medical 和 480 Biomedical的董事会观察员。他取得了 Harvard Medical School的遗传学哲学博士学位，以及Rutgers College的生物学学士学位。
- Kevin Bitterman has served as a member of our board of directors since June 2018. Dr. Bitterman currently serves as a partner at venture firm Atlas Venture, or Atlas, a venture capital firm, where he has been employed since June 2017 and where he focuses on investments in life science companies. Prior to joining Atlas in June 2017 Dr. Bitterman was a partner at Polaris Partners, an investment firm, as a member of the healthcare team since July 2004. Dr. Bitterman was also the founding CEO at Editas Medicine Inc., a pharmaceutical company, Visterra Inc., a biotechnology company, and Morphic Rock, LLC, a biotechnology company. During the past five years, Dr. Bitterman has served on the board of directors of Editas Medicine, Inc., Kala Pharmaceuticals, Inc., a pharmaceutical company, Genocea Biosciences, Inc., a biosciences company, as well as on the board of directors of several private companies. Dr. Bitterman also serves as board chair of the New England Venture Capital Association. Dr. Bitterman received a B.A. in biology from Rutgers College and a Ph.D. in genetics from Harvard Medical School.
高管简历
中英对照 | 中文 | 英文- Jonathan Young
Jonathan Young于2017年4月至2018年9月担任我们的联合创始人，总裁兼首席执行官，并自2018年9月起担任我们的联合创始人，执行Vice President兼首席运营官。加入公司之前，Young博士于2016年10月至2018年9月担任风险投资公司Apple Tree Partners的风险合伙人。2014年8月至2016年10月，他担任BraeburnPharmaceuticals，Inc.政策/宣传and General Counsel Vice President2006年10月至2014年8月，Young博士在Foxkiser LLP（一家法律服务公司）担任越来越重要的职务，最终担任and General Counsel的合伙人。Young博士拥有弥赛亚学院（Messiah College）历史学学士学位，北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）美国历史硕士学位和博士学位以及耶鲁大学法学院（Yale Law School）法学博士学位。
Jonathan Young served as our co-founder, President and Chief Executive Officer from April 2017 to September 2018 and since September 2018 as our co-founder, Executive Vice President and Chief Operating Officer. Before joining the Company, Dr. Young served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to September 2018. From August 2014 to October 2016 he served as Vice President of Policy/Advocacy and General Counsel at Braeburn Pharmaceuticals, Inc. From October 2006 through August 2014 Dr. Young served in positions of increasing responsibility at FoxKiser LLP, a legal services firm, ultimately as Partner and General Counsel. Dr. Young holds a B.A. in history from Messiah College, an M.A. and Ph.D. in American history from the University of North Carolina at Chapel Hill and a J.D. from Yale Law School.- Jonathan Young于2017年4月至2018年9月担任我们的联合创始人，总裁兼首席执行官，并自2018年9月起担任我们的联合创始人，执行Vice President兼首席运营官。加入公司之前，Young博士于2016年10月至2018年9月担任风险投资公司Apple Tree Partners的风险合伙人。2014年8月至2016年10月，他担任BraeburnPharmaceuticals，Inc.政策/宣传and General Counsel Vice President2006年10月至2014年8月，Young博士在Foxkiser LLP（一家法律服务公司）担任越来越重要的职务，最终担任and General Counsel的合伙人。Young博士拥有弥赛亚学院（Messiah College）历史学学士学位，北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）美国历史硕士学位和博士学位以及耶鲁大学法学院（Yale Law School）法学博士学位。
- Jonathan Young served as our co-founder, President and Chief Executive Officer from April 2017 to September 2018 and since September 2018 as our co-founder, Executive Vice President and Chief Operating Officer. Before joining the Company, Dr. Young served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to September 2018. From August 2014 to October 2016 he served as Vice President of Policy/Advocacy and General Counsel at Braeburn Pharmaceuticals, Inc. From October 2006 through August 2014 Dr. Young served in positions of increasing responsibility at FoxKiser LLP, a legal services firm, ultimately as Partner and General Counsel. Dr. Young holds a B.A. in history from Messiah College, an M.A. and Ph.D. in American history from the University of North Carolina at Chapel Hill and a J.D. from Yale Law School.
- William White
自2019年4月以来，William White一直担任我们的执行Vice President，首席财务官和企业发展主管。在加入我们公司之前，怀特先生于2017年9月至2019年3月担任德意志银行董事总经理兼美国生命科学投资银行业务主管。在担任该职位之前，怀特先生于2006年5月至2017年9月担任花旗集团梦百合投资银行业务董事总经理。此前，他曾于2004年4月至2006年3月担任高盛（Goldman，Sachs&Co.）梦百合投资银行业务Vice President。White先生在普林斯顿大学（Princeton University）获得A.B.，在哈佛大学（Harvard University）获得M.P.，在哥伦比亚大学（Columbia University）获得J.D.。
William White has served as a member of our board of directors since May 2021. Since April 2019 Mr. White has served as chief financial officer and head of corporate development and treasurer of Akero Therapeutics. From September 2017 to March 2019 Mr. White served as a managing director and head of US life sciences investment banking at Deutsche Bank. From May 2006 to September 2017 Mr. White was a managing director in healthcare investment banking at Citigroup. From November 2000 to March 2006 Mr. White served as an associate and vice president in healthcare investment banking at Goldman, Sachs & Co. Mr. White currently serves on the board of directors of Disc Medicine, Inc., a private hematology company. Mr. White received an A.B. from Princeton University, an M.P.P. from Harvard University and a J.D. from Columbia University.- 自2019年4月以来，William White一直担任我们的执行Vice President，首席财务官和企业发展主管。在加入我们公司之前，怀特先生于2017年9月至2019年3月担任德意志银行董事总经理兼美国生命科学投资银行业务主管。在担任该职位之前，怀特先生于2006年5月至2017年9月担任花旗集团梦百合投资银行业务董事总经理。此前，他曾于2004年4月至2006年3月担任高盛（Goldman，Sachs&Co.）梦百合投资银行业务Vice President。White先生在普林斯顿大学（Princeton University）获得A.B.，在哈佛大学（Harvard University）获得M.P.，在哥伦比亚大学（Columbia University）获得J.D.。
- William White has served as a member of our board of directors since May 2021. Since April 2019 Mr. White has served as chief financial officer and head of corporate development and treasurer of Akero Therapeutics. From September 2017 to March 2019 Mr. White served as a managing director and head of US life sciences investment banking at Deutsche Bank. From May 2006 to September 2017 Mr. White was a managing director in healthcare investment banking at Citigroup. From November 2000 to March 2006 Mr. White served as an associate and vice president in healthcare investment banking at Goldman, Sachs & Co. Mr. White currently serves on the board of directors of Disc Medicine, Inc., a private hematology company. Mr. White received an A.B. from Princeton University, an M.P.P. from Harvard University and a J.D. from Columbia University.
- Timothy Rolph
Timothy Rolph自2017年4月起担任我们的联合创始人兼首席科学官。在加入我们公司之前，Rolph博士于2016年10月至2018年9月担任风险投资公司Apple Tree Partners的风险合伙人。1994年3月至2016年10月，Rolph博士在制药公司辉瑞公司担任多个职位，最近的职位是2014年7月至2016年10月担任高级副总裁，项目价值提升，2009年1月至2014年6月担任心血管、代谢和内分泌疾病首席科学官。在辉瑞公司任职期间，罗尔夫博士还负责该公司的FGF21项目。Dr.Rolph持有B.SC.在伦敦大学获得生物化学博士学位，在牛津大学获得肌肉发育博士学位。
Timothy Rolph has served as our co-founder and Chief Scientific Officer since April 2017. Before joining our company, Dr. Rolph served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to September 2018. From March 1994 to October 2016 Dr. Rolph served in various roles at Pfizer Inc., a pharmaceutical company, most recently as Senior Vice President, Program Value Enhancement from July 2014 to October 2016 and as Chief Scientific Officer, Cardiovascular and Metabolic and Endocrine Disease from January 2009 to June 2014. During his tenure at Pfizer Inc., Dr. Rolph also oversaw the Company's FGF21 program. Dr. Rolph holds a B.Sc. in biochemistry from the University of London and a DPhil in muscle development from University of Oxford.- Timothy Rolph自2017年4月起担任我们的联合创始人兼首席科学官。在加入我们公司之前，Rolph博士于2016年10月至2018年9月担任风险投资公司Apple Tree Partners的风险合伙人。1994年3月至2016年10月，Rolph博士在制药公司辉瑞公司担任多个职位，最近的职位是2014年7月至2016年10月担任高级副总裁，项目价值提升，2009年1月至2014年6月担任心血管、代谢和内分泌疾病首席科学官。在辉瑞公司任职期间，罗尔夫博士还负责该公司的FGF21项目。Dr.Rolph持有B.SC.在伦敦大学获得生物化学博士学位，在牛津大学获得肌肉发育博士学位。
- Timothy Rolph has served as our co-founder and Chief Scientific Officer since April 2017. Before joining our company, Dr. Rolph served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to September 2018. From March 1994 to October 2016 Dr. Rolph served in various roles at Pfizer Inc., a pharmaceutical company, most recently as Senior Vice President, Program Value Enhancement from July 2014 to October 2016 and as Chief Scientific Officer, Cardiovascular and Metabolic and Endocrine Disease from January 2009 to June 2014. During his tenure at Pfizer Inc., Dr. Rolph also oversaw the Company's FGF21 program. Dr. Rolph holds a B.Sc. in biochemistry from the University of London and a DPhil in muscle development from University of Oxford.
- Kitty Yale
Kitty Yale自2018年10月起担任我们的首席开发官。在加入公司之前，Yale女士于2001年10月至2018年10月在生物技术公司吉利德科学公司担任多个职位，担任高级临床研究和运营职位，并领导公司肿瘤，艾滋病毒，炎症和肝病试验的全球临床运营和管理。最近，耶鲁女士于2016年7月至2018年10月担任吉利德科学公司临床运营Vice President。Yale女士拥有学士学位。Glasgow Caledonian University应用生物学学士学位。
Kitty Yale has served as our Chief Development Officer since October 2018. Before joining the Company, Ms. Yale served in various roles at Gilead Sciences, Inc., a biotechnology company, from October 2001 to October 2018 where she held senior clinical research and operations roles and led global clinical operations and management of the Company's oncology, HIV, inflammation and liver disease trials. Most recently, Ms. Yale served as Vice President of Clinical Operations at Gilead Sciences, Inc. from July 2016 to October 2018. Ms. Yale holds a B.Sc. in applied biology from Glasgow Caledonian University.- Kitty Yale自2018年10月起担任我们的首席开发官。在加入公司之前，Yale女士于2001年10月至2018年10月在生物技术公司吉利德科学公司担任多个职位，担任高级临床研究和运营职位，并领导公司肿瘤，艾滋病毒，炎症和肝病试验的全球临床运营和管理。最近，耶鲁女士于2016年7月至2018年10月担任吉利德科学公司临床运营Vice President。Yale女士拥有学士学位。Glasgow Caledonian University应用生物学学士学位。
- Kitty Yale has served as our Chief Development Officer since October 2018. Before joining the Company, Ms. Yale served in various roles at Gilead Sciences, Inc., a biotechnology company, from October 2001 to October 2018 where she held senior clinical research and operations roles and led global clinical operations and management of the Company's oncology, HIV, inflammation and liver disease trials. Most recently, Ms. Yale served as Vice President of Clinical Operations at Gilead Sciences, Inc. from July 2016 to October 2018. Ms. Yale holds a B.Sc. in applied biology from Glasgow Caledonian University.
- Andrew Cheng
Andrew Cheng自2018年9月起担任我们的总裁兼首席执行官。在加入公司之前，程博士曾于2018年3月至2018年9月在生物技术公司吉利德科学公司担任首席医疗官，2015年2月至2018年9月担任执行Vice President，2009年2月至2015年2月担任高级副总裁。在他近20年的任期内，他负责HIV项目的临床开发，产生了11个FDA/EMA批准的产品。他过去的职责还包括医疗事务和开发运营部监管事务的创建、临床运营、药物警戒、项目管理、临床药理学和生物识别，涵盖多个治疗领域的临床开发支持，包括肿瘤学、炎症、呼吸、心血管、艾滋病毒和肝脏疾病。Cheng博士曾在生物技术公司Syntimmune，Inc.的董事会任职，该公司被Alexion收购。Cheng博士拥有The Johns Hopkins University生物学学士学位和Columbia University College of Physicians and Surgeons细胞和分子生物学硕士学位和博士学位。他在加州大学洛杉矶分校（UCLA）完成了内科住院医师资格，并获得了内科委员会认证。
Andrew Cheng,has served as a member of Board since May 2017. Dr. Cheng has served as the President and Chief Executive Officer, as well as a director, of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since September 2018. Dr. Cheng has served as non-executive director for MorphoSys AG (Nasdaq: MOR) from May 2022 until its acquisition in February 2024. From August 2019 to May 2022, Dr. Cheng served as a non-executive director for Arbutus Biopharma Corporation (Nasdaq: ABUS), a biopharmaceutical company. Before joining Akero, Dr. Cheng was at Gilead as Chief Medical Officer from March 2018 to September 2018, Executive Vice President from February 2015 to September 2018, and Senior Vice President from February 2009 to February 2015. From April 2018 to November 2018, Dr. Cheng served on the board of directors of Syntimmune, Inc., a biotechnology company, which was acquired by Alexion Pharmaceuticals Inc. Dr. Cheng holds a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine.- Andrew Cheng自2018年9月起担任我们的总裁兼首席执行官。在加入公司之前，程博士曾于2018年3月至2018年9月在生物技术公司吉利德科学公司担任首席医疗官，2015年2月至2018年9月担任执行Vice President，2009年2月至2015年2月担任高级副总裁。在他近20年的任期内，他负责HIV项目的临床开发，产生了11个FDA/EMA批准的产品。他过去的职责还包括医疗事务和开发运营部监管事务的创建、临床运营、药物警戒、项目管理、临床药理学和生物识别，涵盖多个治疗领域的临床开发支持，包括肿瘤学、炎症、呼吸、心血管、艾滋病毒和肝脏疾病。Cheng博士曾在生物技术公司Syntimmune，Inc.的董事会任职，该公司被Alexion收购。Cheng博士拥有The Johns Hopkins University生物学学士学位和Columbia University College of Physicians and Surgeons细胞和分子生物学硕士学位和博士学位。他在加州大学洛杉矶分校（UCLA）完成了内科住院医师资格，并获得了内科委员会认证。
- Andrew Cheng,has served as a member of Board since May 2017. Dr. Cheng has served as the President and Chief Executive Officer, as well as a director, of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since September 2018. Dr. Cheng has served as non-executive director for MorphoSys AG (Nasdaq: MOR) from May 2022 until its acquisition in February 2024. From August 2019 to May 2022, Dr. Cheng served as a non-executive director for Arbutus Biopharma Corporation (Nasdaq: ABUS), a biopharmaceutical company. Before joining Akero, Dr. Cheng was at Gilead as Chief Medical Officer from March 2018 to September 2018, Executive Vice President from February 2015 to September 2018, and Senior Vice President from February 2009 to February 2015. From April 2018 to November 2018, Dr. Cheng served on the board of directors of Syntimmune, Inc., a biotechnology company, which was acquired by Alexion Pharmaceuticals Inc. Dr. Cheng holds a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine.